PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 8, 2014--
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the pricing
of its previously announced public offering of 1,600,000 shares of its
common stock at a public offering price of $64.00 per share. After
deducting underwriting discounts and commissions and estimated offering
expenses, Pacira will receive net proceeds of approximately $96.0
million in the offering. In addition, Pacira has granted the
underwriters a 30-day option to purchase up to 240,000 additional shares
of common stock. The offering is expected to close on or about April 14,
2014, subject to customary closing conditions.
Jefferies LLC, Barclays Capital Inc. and BofA Merrill Lynch are acting
as the joint book-running managers for the offering. Wedbush PacGrow
Life Sciences and Brean Capital, LLC are acting as co-managers for the
A shelf registration statement relating to the shares was filed with the
SEC and is effective. A preliminary prospectus supplement related to the
offering was filed with the SEC on April 7, 2014 and is available on the
SEC’s website located at http://www.sec.gov.
A final prospectus supplement related to the offering will be filed with
the SEC. Copies of the final prospectus supplement and the accompanying
prospectus relating to this offering may be obtained from Jefferies LLC,
Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue,
12th Floor, New York, NY, 10022, by telephone at 877-547-6340 or by
email at Prospectus_Department@Jefferies.com,
from Barclays Capital Inc., c/o Broadridge Financial Solutions, at 1155
Long Island Avenue, Edgewood, NY 11717, or by calling 1-888-603-5847 or
by emailing Barclaysprospectus@broadridge.com
or from BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn:
Prospectus Department, or via e-mail at email@example.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities. There shall not be any
sale of these securities in any state or other jurisdiction in which
such offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or other jurisdiction.
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) is a specialty
pharmaceutical company focused on the clinical and commercial
development of new products that meet the needs of acute care
practitioners and their patients. The company’s current emphasis is the
development of non-opioid products for postsurgical pain control, and
its lead product, EXPAREL® (bupivacaine liposome injectable suspension),
was commercially launched in the United States in April 2012. EXPAREL
and two other products have utilized the Pacira proprietary product
delivery technology DepoFoam®, a unique platform that encapsulates drugs
without altering their molecular structure and then releases them over a
desired period of time.
Source: Pacira Pharmaceuticals, Inc.
Pacira Pharmaceuticals, Inc.
Jessica Cho, 973-254-3574